echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Gilead Sciences has published the latest data analysis positive results for its antibody-coupled drug Trodelvy in patients with HR-positive/HER2-negative metastatic breast cancer who had undergone multiple pre-treatments

    Gilead Sciences has published the latest data analysis positive results for its antibody-coupled drug Trodelvy in patients with HR-positive/HER2-negative metastatic breast cancer who had undergone multiple pre-treatments

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gilead Sciences today announced the latest positive results


    Patients in the Trodelvy treatment group achieved statistically significant and clinically significant improvements in overall survival (OS) Gilead has filed a Supplemental Biologics Licensing Application (sBLA) with the U.


    Trodelvy is a "first-in-class" antibody-conjugated drug


    Trodelvy is a "first-in-class" antibody-conjugated drug


    The median overall survival of the key secondary endpoints published this time showed that the median overall survival of Trodelvy and the control group was 14.


    The median overall survival of Trodelvy and control groups was 14.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.